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Abstract Endogenous ceramide is produced by the action of
acidic or neutral sphingomyelinases (SMase) in response to
stimuli such as proinflammatory cytokines or other inducers of
stress. Interleukin-1L (IL-1L) is known to stimulate ceramide
formation in rat renal mesangial cells ; however, the respective
subtype of SMase and its regulation have not been investigated.
We found that IL-1L induced an increase in endogenous ceramide
levels via the action of a neutral SMase but not an acidic SMase
in rat mesangial cells. Cytokine-induced activation of neutral
SMase was inhibited by stimulation of protein kinase C (PKC)
by the phorbol ester TPA which caused a reduction of ceramide
back to control levels. This inhibitory effect of TPA was reversed
by the specific PKC-inhibitor Ro-318220. Long-term incubation
(24 h) of mesangial cells with TPA, which downregulates PKC-K,
-N, and -O isoenzymes, resulted in a recovery of IL-1L-stimulated
neutral SMase activity as well as ceramide formation. These
data implicate an important modulatory function of PKC in
ceramide production in IL-1L-activated mesangial cells.
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1. Introduction
Rat renal mesangial cells are a suitable model system to
study cytokine-regulated mechanisms which re£ect proin£am-
matory processes involved in the pathogenesis of glomerulo-
nephritis [1]. Under pathological conditions, mesangial cells
have the potential to produce a cascade of in£ammatory me-
diators including eicosanoids, nitric oxide and other reactive
oxygen species as well as growth factors [2]. Another more
recently characterized class of lipid second messengers are
ceramides which have emerged as potent mediators in the
regulation of proliferation of di¡erent cell systems [3^6]. In
mesangial cells ceramides have been shown to activate the c-
Raf kinase via speci¢c binding to this enzyme [7]. Endogenous
ceramides can be formed by the stimulation of di¡erent sphin-
gomyelinases (SMase) by in£ammatory cytokines [8]. The ac-
tion of a neutral cytosolic or membrane-bound form and an
acidic form located in lysosomes determine the major route of
sphingomyelin degradation resulting in ceramide and phos-
phocholine. The acidic form of SMase had already been
cloned and is well characterized [9]. Recently, a neutral SMase
was cloned in human embryonic kidney 293 cells [10]. In
mesangial cells the activation of an SMase by IL-1L was de-
scribed without further distinguishing the di¡erent isoenzymes
[11]. The aim of this study was to investigate which type of
SMase is responsible for IL-1L-stimulated ceramide forma-
tion. Furthermore, we looked for regulatory signaling path-
ways that might interfere with the hydrolysis of SM by the
respective SMase. We found that IL-1L stimulated a neutral
SMase, and that this enzyme as well as ceramide formation
were inhibited by TPA treatment. This inhibition could be
reversed completely by speci¢c PKC inhibitors or by down-
regulation of TPA-sensitive PKC-isoenzymes indicating that
PKC may act as an early negative modulator of IL-1L-in-
duced signaling through the SM pathway.
2. Materials and methods
2.1. Materials
Recombinant IL-1L was generously supplied by Dr. C. Rordorf,
Novartis Pharma, Basel, Switzerland. [1-14C]Oleic acid, L-[3-14C]serine
and [N-methyl-14C]sphingomyelin were from Amersham-Buchler,
Frankfurt, Germany. TPA was purchased from Sigma (Munich, Ger-
many). {3-[1-[3-(Amidinothio)propyl-1H-indoyl]-3-yl]-3-(1-methyl-1H-
indoyl-3-yl)maleimide methane sulfonate}, Ro-318220, was a generous
gift of F. Ho¡mann-LaRoche (Basel, Switzerland). All cell culture
media and nutrients were from Gibco-BRL (Eggenstein, Germany),
and all other chemicals used were from either Merck (Darmstadt,
Germany) or Fluka (Deisenhofen, Germany).
2.2. Cell culture
Rat renal mesangial cells were cultivated as described previously
[12]. The cells were grown in RPMI 1640 supplemented with 10%
fetal calf serum, penicillin (100 units/ml), streptomycin (100 Wg/ml)
and bovine insulin (0.66 units/ml). Twenty-four hours prior to stim-
ulation and during the experiments cells were incubated in DMEM
containing 0.1 mg/ml fatty acid-free bovine serum albumin (BSA).
2.3. Assay of neutral and acidic sphingomyelinase
The assays for detecting activity of a neutral and an acidic SMase
were performed according to Robinson et al. [13] under optimal assay
conditions for the respective enzyme using [N-methyl-14C]sphingo-
myelin. Brie£y, for determination of the activity of the neutral SMase
aliquots of the cell lysates containing 10 Wg of protein were incubated
with [N-methyl-14C]sphingomyelin (0.05 WCi) in 50 Wl ¢nal volume of
20 mM HEPES, 1 mM MgCl2 bu¡er, pH 7.4 at 37‡C for 2 h. The
amount of [14C]phosphocholine liberated from the substrate was as-
sessed by partitioning the reaction mixture with 800 Wl chloroform/
methanol (2:1 by vol.) and 250 Wl water, and counting the radioac-
tivity of the aqueous phase (200 Wl) in a liquid scintillation counter.
To measure acidic SMase activity, aliquots of cell lysates were incu-
bated with [N-methyl-14C]sphingomyelin in 50 Wl ¢nal vol. of 250 mM
sodium acetate, 1 mM EDTA bu¡er, pH 5.0 and the amount of
[14C]phosphocholine produced was determined as described for the
neutral SMase assay.
2.4. Lipid extraction and analysis of endogenous ceramides
Cells were prelabeled for 24 h with L-[3-14C]serine (0.4 WCi/ml) in
DMEM plus 0.1 mg/ml fatty acid-free BSA, and after medium change
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they were treated with the compounds to be tested. The reaction was
stopped by removing the supernatant and adding 2 ml ice-cold meth-
anol to the cells. Cellular lipids were extracted with 2 ml 1 N HCl and
2 ml chloroform according to Bligh and Dyer [14]. The concentrated
chloroform phases were applied to silica gel 60 TLC plates and de-
veloped in a ¢rst run for the ¢rst 10 cm in chloroform-methanol-25%
ammonia (65:35:7.5 by vol.) and in a second run to the top of the
plate in chloroform-methanol-acetic acid (90:10:10 by vol.). The de-
tection and quanti¢cation of ceramides was performed by scanning
the lanes using a Linear Analyzer (Berthold, Wildbad, Germany). For
localization of ceramides on the TLC-plates C16-ceramide as well as
ceramides from bovine brain (Sigma) were used as reference substan-
ces and were visualized by iodine vapor.
3. Results
First we investigated whether an acidic or a neutral SMase
is activated in mesangial cells after IL-1L treatment. To this
end a time course of [14C]phosphocholine release from radio-
actively labeled sphingomyelin was performed for up to 3 h
under the speci¢c conditions required for optimal activity of
acidic SMase and neutral SMase, respectively. As shown in
Fig. 1A we found a rapid and transient increase in neutral
SMase activity with a maximum after 10 min of IL-1L treat-
ment. During this time period no activation of an acidic
SMase could be observed (Fig. 1B). In parallel we measured
the ceramide formation in [14C]serine-prelabeled cells after IL-
1L treatment. In Fig. 1C it is shown that ceramide formation
followed the neutral SMase activity with a rapid and transient
increase 20 min after IL-1L treatment.
When cells were preincubated with TPA, a direct activator
of PKC, for 10 min and then treated with IL-1L, the neutral
SMase activity (Fig. 2A) as well as ceramide formation (Fig.
2B) were completely inhibited. During this short-term incuba-
tion period TPA alone did not stimulate an increase in ceram-
ide levels. These data indicate that phorbol ester-activated
PKC isoenzymes negatively regulate IL-1L-stimulated neutral
SMase activation and ceramide formation.
In earlier studies we have shown that a 24-h treatment of
mesangial cells with 500 nM TPA is necessary to downregu-
late the TPA-sensitive PKC-isoforms -K, -N and -O and to
remove cellular functions mediated by these isoenzymes [15^
17]. Performing di¡erent preincubation periods with TPA the
e¡ects on neutral SMase activity and ceramide formation were
investigated. The data in Fig. 2 show that after a 4^8-h treat-
ment with TPA the IL-1L-stimulated neutral SMase activity
(Fig. 2A) and ceramide formation (Fig. 2B) were still com-
pletely inhibited indicating that under these conditions PKC-
isoenzymes were still active. However, after a 24-h treatment
with TPA the activity of neutral SMase as well as ceramide
formation were fully reconstituted thus indicating that one or
more PKC-isoenzymes seem to be responsible for the inhib-
itory e¡ect of TPA on SM hydrolysis.
In order to con¢rm the role of PKC as a negative regulator
of IL-1L-induced neutral SMase activation we used Ro-
318220 as a speci¢c inhibitor of PKC [18]. The data in Fig.
3 show that Ro-318220 inhibited TPA action and resulted in a
complete recovery of IL-1L-stimulated neutral SMase activity.
Under this condition we also detected a nearly complete re-
constitution of ceramide formation with Ro-318220 reaching
86 þ 4% (n = 3).
4. Discussion
In this study we could show that (i) the activation of a
neutral SMase and formation of its product ceramide are
early events in the signaling pathway induced by IL-1L and
(ii) that this e¡ect can be inhibited by PKC in mesangial cells.
Activation of PKC is already known to inhibit hormone-
stimulated phosphoinositide signaling in mesangial cells [19^
21]. Now with the inhibitory e¡ect on neutral SMase activa-
tion we report a new negative regulatory function of PKC
which may contribute to the coordination of signal £ow in
di¡erent signalling pathways in mesangial cells.
A membrane-associated neutral SMase activity has been
known for many years, and several studies have suggested
FEBS 21198 30-11-98
Fig. 1. Time course of IL-1L-stimulated activity of neutral (A) and
acidic SMase (B) and ceramide formation (C) in rat mesangial cells.
For measuring neutral (A) and acidic SMase activity (B) cells were
incubated with IL-1L (2 nM; b) or vehicle (a) for the time points
indicated. Cell lysates were assayed for neutral and acidic SMase ac-
tivity with [N-methyl-14C]sphingomyelin and analyzed for released
[14C]phosphocholine as described in Section 2. For detection of en-
dogenous ceramide (C) cells were prelabeled for 24 h with
[14C]serine and then treated with IL-1L (b) or vehicle (a) for the
time points indicated. After lipid extraction ceramides were analyzed
by thin layer chromatography as described in Section 2. Each value
represents the means þ S.D. of 3 experiments, n = 3. Statistical analy-
sis in A: ***P6 0.001, *P6 0.05 (Student’s t-test). None of the
data points in B was statistically signi¢cant from its corresponding
control value (Student’s t-test).
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an activation of this enzyme in response to cytokines and
oxidative stress (for review see [22]). However, the mecha-
nisms involved in regulating neutral SMase remained poorly
de¢ned. The recent cloning of the enzyme [10] may help to
elucidate the regulation of neutral SMase signalling.
Earlier studies of our group have shown that phorbol ester-
activated PKC isotypes interfere with IL-1L-stimulated signal-
ing by inhibiting the expression of proin£ammatory genes
such as inducible nitric oxide synthase [23] and group IIA
phospholipase A2 (unpublished observations). As possible tar-
gets of PKC isoenzymes three possibilities were discussed: (i)
phosphorylation and activation of transcription factors by
PKC [24] ; (ii) phosphorylation of the IL-1 receptor itself
[25]; and (iii) phosphorylation of IL-1-receptor-associated
kinases (IRAKs; [26]).
In our study we focussed on activation of the neutral
SMase which is an early event in IL-1L signalling. Coincuba-
tion of mesangial cells with cytokine and phorbol ester neg-
atively modulated the IL-1L-stimulated activation of neutral
SMase thus leading to a complete inhibition of ceramide for-
mation. This inhibition was reversed by downregulation of all
TPA-sensitive PKC isoenzymes. In our earlier studies we ob-
served that PKC-O seems to be important for the negative
modulation of cytokine-induced gene expression of inducible
nitric oxide synthase and group IIA phospholipase A2.
Whether this is true also for neutral SMase regulation remains
to be elucidated.
Further studies have to be performed to characterize the
exact regulation of the neutral SMase by IL-1L-receptor acti-
vation and the target for PKC that allows for negative regu-
lation of neutral SMase activity. In this context it is worth
noting that the protein sequence of the neutral SMase shows
¢ve putative PKC-motifs ([S-T]-X-X-D-E) which suggests
possible direct regulation by PKC-mediated phosphorylation.
Moreover, we have recently shown that ceramide selectively
binds to PKC-K and -N isoenzymes in mesangial cells [27]. It
will be of high priority to evaluate whether endogenous cer-
amide formed in mesangial cells after IL-1L stimulation acti-
vates one or both of these PKC isoforms, thereby inactivating
neutral SMase and switching o¡ ceramide formation in a neg-
ative feedback loop.
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